Table 2

 Biomarker levels of patients receiving infliximab and those receiving etanercept, versus normal levels

Biomarker levelsNormal healthy rangeInfliximabEtanercept
COL 2–3/4 C long neoepitope, type II collagen cleavage by collagenase; CTX-1, C-telopeptide-1; ICAM-1, intracellular adhesion molecule-1; IL, interleukin; VEGF, vascular endothelial growth factor.
*An IQR could not be determined because the majority of normal donors were below the lower limit of quantification (LLOQ).
†The majority of normal healthy donors had serum levels of IL8 that were below the LLOQ for the assay (15.6 pg/ml); therefore, a normal range could not be determined.
ICAM-1 (ng/ml)220.6–317.8342.3 (153.9–867.9)382.8 (200.9–707.6)
(n = 13)
CTX-1 (ng/ml)0.20–1.170.3 (0.1–0.9)0.3 (0.1–0.4)
(n = 10)
IL8 (pg/ml)*Unable to be determined†35.5 (17.7–184.7)34.0 (19.7–180.6)
COL 2–3/4 C long neoepitope (ng/ml)38.4–100.5103.7 (62.3–361.1)80.4 (58.2–94.3)
(n = 15)
VEGF (pg/ml)70.5–702.6238.6 (67.3–1192)354.9 (90.5–937.0)
(n = 13)
Osteocalcin (ng/ml)5.9–40.313.4 (1.7–33.6)9.3 (1.7–28.7)
(n = 12)
Matrix metalloproteinase-3 (ng/ml)6.4–29.119.1 (4.1–170.3)17.7 (6.8–68.6)
(n = 20)